Archives
-
Disulfiram: Separating Proteasome and Pyroptosis Signals
2026-09-20
Disulfiram is a dopamine β-hydroxylase inhibitor with distinct proteasome- and inflammasome-related research applications. This guide develops an assay-first framework for separating apoptotic cancer cell death from gasdermin D–dependent pyroptosis and interpreting copper-dependent activity.
-
PPP1R3G–PP1γ Control of RIPK1 Cell Death
2026-09-19
The study identifies PPP1R3G as a regulatory subunit that recruits PP1γ to dephosphorylate inhibitory sites on RIPK1, enabling RIPK1-dependent apoptosis and type I necroptosis. Its genetic, biochemical, and mouse-model evidence clarifies how phosphatase activity controls inflammatory cell death and provides a framework for separating RIPK1 activation from parallel NF-κB signaling.
-
Palbociclib (PD0332991) Isethionate in Cell Assays
2026-09-18
Learn how Palbociclib (PD0332991) Isethionate, SKU A8335, can improve the design and interpretation of cell-cycle, viability, proliferation, and cytotoxicity experiments. This scenario-based guide covers mechanism, dosing, storage, assay controls, data interpretation, and practical supplier selection.
-
Guanabenz Acetate: α2 Receptor Assay Workflows
2026-09-18
Build subtype-aware α2-adrenergic assays with a DMSO-compatible workflow for GPCR pharmacology and neuroimmune studies. The approach pairs concentration-response testing with stress-granule, GADD34, and IRF3 readouts while clearly separating established evidence from exploratory applications.
-
Fast-Dissociating Antibodies for Single-Molecule Imaging
2026-09-17
Miyoshi and colleagues developed a semi-automated single-molecule TIRF assay that identifies specific, fast-dissociating monoclonal antibodies directly from hybridoma cultures. Their results show that rapid antibody exchange can support multiplex super-resolution imaging and reveal dynamic espin turnover within stable actin cores of inner-ear hair-cell stereocilia.
-
Cefazedone PK/PD in Community-Acquired Pneumonia
2026-09-17
A small clinical pharmacokinetic/pharmacodynamic study evaluated whether intravenous cefazedone sodium 2 g every 12 hours provides adequate exposure for mild to moderate community-acquired pneumonia. Its main contribution was to connect clinical response and microbiological clearance with the time that free drug concentrations exceeded the pathogen MIC, supporting the studied regimen while highlighting the need for larger comparative trials.
-
Vincristine Sulfate: A Mechanism-to-Assay Guide
2026-09-16
Vincristine sulfate is a powerful microtubule-targeting tool for cancer research. This guide connects tubulin biology, orthogonal assay design, translational interpretation, and lessons from systematic drug-repositioning research.
-
Biotin-16-UTP for RNA Biomarker Validation
2026-09-16
Biotin-16-UTP converts an in vitro-transcribed RNA into a capture-ready molecular probe. This guide explains how biotin-labeled uridine triphosphate can translate RNASEH1-AS1 biomarker evidence into controlled RNA detection, localization, and interaction assays.
-
Necrostatin 2: A Mechanism-First Research Guide
2026-09-15
Necrostatin 2 (Nec-2) is a nanomolar small-molecule tool for probing programmed necrotic cell death. This mechanism-first guide explains how to use Nec-2 alongside membrane-integrity assays and ferroptosis research without conflating distinct cell-death pathways.
-
Cryptosporidium AdhE Inhibition by Antifungal Imidazoles
2026-09-15
The reference study establishes the bacterial-type bifunctional aldehyde/alcohol dehydrogenase CpAdhE as a chemically vulnerable metabolic target in Cryptosporidium parvum. Through library screening, enzyme kinetics, parasite growth assays, and cytotoxicity testing, the authors show that several antifungal imidazoles have low-micromolar activity and provide a rationale for further anti-cryptosporidial drug discovery.
-
Foretinib, Immunogenic Cell Death, and CD47 Blockade
2026-09-14
The reference study shows that foretinib, a c-Met/VEGFR2 inhibitor, can induce immunogenic cell death in colorectal cancer by activating p53, increasing DR5, and promoting calreticulin exposure, ATP release, and HMGB1 secretion. These effects remodel the tumor immune microenvironment and help explain the enhanced antitumor activity observed when foretinib is combined with anti-CD47 immunotherapy.
-
LGMN Editing with Cas9 mRNA Represses Metastasis
2026-09-14
Wang and colleagues developed a lipid nanoparticle strategy for co-delivering Cas9 mRNA and guide RNA to disrupt LGMN, a lysosomal protease associated with aggressive breast cancer behavior. The study links this editing workflow to impaired lysosomal/autophagic degradation and reduced cancer-cell clonogenicity, migration, invasion, and experimental lung metastasis, while also offering practical lessons for T7-promoter-driven RNA production.
-
Mecamylamine Hydrochloride: Causal nAChR Tests
2026-09-13
Mecamylamine hydrochloride offers a reversible pharmacological way to test whether nicotinic signaling contributes to gut-brain and neuropsychiatric phenotypes. This article develops a causal assay framework grounded in recent Bacteroides fragilis epilepsy research while defining what the antagonist can—and cannot—prove.
-
Regorafenib Workflows for Cancer Biology Research
2026-09-12
Regorafenib (BAY 73-4506) supports integrated studies of kinase signaling, angiogenesis, tumor-cell invasion, and melanoma biology. This workflow-centered guide connects concentration-controlled cell assays with RRM2/ERK/E2F3 mechanism testing and tumor xenograft models.
-
ACSL1, FSP1, and Ferroptosis in Ovarian Cancer
2026-09-11
The reference study identifies an ACSL1–FSP1 axis that links fatty-acid metabolism to ferroptosis resistance and platinum failure in ovarian cancer spheroids. Its central innovation is showing that ACSL1 promotes FSP1 N-myristoylation, stability, and membrane localization, thereby strengthening antioxidant defense against lipid peroxidation.